1 / 49

Scompenso cardiaco e sindromi correlate: non trascuriamo lo “sleep disorder”

Scompenso cardiaco e sindromi correlate: non trascuriamo lo “sleep disorder”. Michele Emdin, Claudio Passino U.O. Medicina Cardiovascolare Fondazione Toscana Gabriele Monasterio Istituto di Fisiologia Clinica CNR, Pisa Scuola Superiore Sant’Anna. Congresso tosco-umbro FIC

ella
Download Presentation

Scompenso cardiaco e sindromi correlate: non trascuriamo lo “sleep disorder”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Scompenso cardiaco e sindromi correlate:non trascuriamo lo “sleep disorder” Michele Emdin,Claudio Passino U.O. Medicina Cardiovascolare Fondazione Toscana Gabriele Monasterio Istituto di Fisiologia Clinica CNR, Pisa Scuola Superiore Sant’Anna Congresso tosco-umbro FIC Montecatini Terme, 14 novembre 2007

  2. 60 sec. 30 sec. …of a patient with probable cardiac asthma: I have little doubt that this was a case of weakened and probably fatty heart, with disease of the aorta…” 0 1 2 3 4 5 6 7 8 9 1 0 Cheyne, J. “A case of Apoplexy, in Which the Fleshy Part of the Heart Was Converted into Fat.”Dublin Hospital Reports, 1818, II, 216.“…For several days his breathing was irregular; it would entirely cease for a quarter of minute, then it would become perceptible, though very low, then by degrees it became heaving and quick, and then it would gradually cease again: this revolution in the state of his breathing occupied about a minute during which there were about thirty acts of respiration...” Stokes, W. “Observations on some Cases of permanently slow Pulse.” Dublin Quart. Jour. Med. Sc.,1846,II,83.“…Then a very feeble, indeed barely perceptible inspiration would take place, followed by another somewhat stronger, until at length high heaving, and even violent breathing was established, which would then subside till the next period of suspension… This was frequently a quarter of minute in duration .

  3. POLYSOMNOGRAPHY

  4. Chronic heart failure:PREVALENCE of Cheyne-Stokes Respiration and Obstructive Apneas % 20* 75 * 450# 100* 34 * NB OA CSR Creteil 1994 Toronto 1999 Grenoble 1999 Cincinnati 2005 Melbourne 1999 * prospective # retrospective

  5. Chronic heart failure: PREVALENCE of Cheyne-Stokes Respiration and Obstructive Apneas 679 patients 5 studies 44% NB AB OA 56% CSR 16% 40%

  6. Sleep characteristics - 81 HF patients Minutes * * * Javaheri S Ital. Circulation 1998-97: 2154

  7. Sleep characteristics - 81 HF patients Sleep efficiency Arousal/h Javaheri S Ital. Circulation 1998-97: 2154

  8. Andamento temporale su un’epoca di 12 min della potenza dell’EEG nelle bande caratteristiche in un soggetto con scompenso cardiaco senza respiro di Cheyne-Stokes. Andamento temporale su un’epoca di 12 min della potenza dell’EEG nelle bande caratteristiche in un soggetto con scompenso cardiaco con respiro di Cheyne-Stokes.

  9. Analisi tramite algoritmo GSTFT Rappresentazione tempo-frequenza del segnale EEG (C4 –A1) in un soggetto con scompenso cardiaco e respiro di Cheyne-Stokes

  10. METODI REGISTRAZIONE CARDIORESPIRATORIA BREVE CHF patient

  11. CSR/PB - 85 pts CSR/PB + 65 pts Prevalence of day-time CSR/PB: Pisa 57% 43% Prevalence in previous studies: - Mortara et al, Circulation 1997: CSR/PB - 64% pts - Ponikowski et al, Circulation 1999: CSR/PB - 66% pts

  12. METODI REGISTRAZIONE CARDIORESPIRATORIA AMBULATORIALE

  13. REGISTRAZIONE CARDIORESPIRATORIA AMBULATORIALE

  14. Effetti clinici del respiro di CS • Cicli di desaturazione arteriosa • Ipossia  disfunzione d’organo/danno endoteliale, vasocostrizione polmonare • Iperattivazione simpatica • Diretta • Indiretta in risposta all’ipossia • Effetti emodinamici (prevalentemente indiretti) •  FC, vasocostrizione  Aumento del post-carico e del lavoro cardiaco • Effetti sulla variabilità della FC e PA

  15. Effetti clinici del respiro di CS

  16.  baroreflex  ergo-chemoreflex BNP - ANP system activation >>> Sympathetic - RAA activation Na - H20 retention – vasoconstriction arrhythmogenesis – tissue ischaemia arrhythmias dyspnoea fatigue sudden death oedema NEURO-HORMONAL IMBALANCE IN HEART FAILURE LV DYSFUNCTION

  17. Cheyne-Stokes e Mortalità nello SCC 16 pazienti con SCC severo in fase di stabilità clinica età media 64 aa, FE < 35% CSR 9/16 (AHI 41± 17 vs 6 ± 5) Hanly PJ, Am J Resp Crit C M 1996;153:272

  18. Valore prognostico del CS notturno nello SCC 62 pz con FE < 35%, NYHA II-III P Lanfranchi et al, Circulation 1999; 99:1435

  19. Valore prognostico RP/CS durante la veglia MT LA Rovere et al., Eur Heart J 2003;

  20. 60 sec. 1 AHI < 30 / hour 0.8 EOV 0.6 AHI > 30 / hour 0.4 proportion surviving AHI > 30 / hour + EOV 0.2 p=0.0001 6 7 8 9 1 0 AHI = apnea-hypopnea index 0 0 10 20 30 months Exercise Recovery Corrà, Circulation 2006 Cheyne-Stokes Respiration during exercise in CHF: impact on PROGNOSIS .

  21. Pathogenesis of CSR in CHF: hypotheses • Central (?) • Hypocapnic (?!) • “Instability loop” (!) • - increased chemosensitivity • - prolonged circulation time

  22. Ipotesi periferica- ipersensibilità chemocettoriale Variazioni di PaCO2 Risposta ventilatoria eccessiva  PaCO2 sotto la soglia apneica Apnea  PaCO2 Ripresa ventilazione

  23. 16 HVR slope 15 14 R= -0.87, p<0.001 Slope = -0.378 13 12 VE/MIN (L/min) 11 10 9 8 7 6 5 SaO2 (%) 80 82 84 86 88 90 92 94 96 98 100 Hypoxic Ventilatory Response 1050 RR interval ms 700 30 Minute Ventilation L/min 0 90 PET CO2 mmHg 0 SaO2 100 % 65 0 6 TIME (min)

  24. 20 HCVR slope 18 R = 0.93, p<0.001 Slope = 1.001 16 VE/MIN (L/min) 14 12 10 8 6 36 38 40 42 44 46 48 50 52 Pet CO2 HypercapnicVentilatory Response 1050 RR interval ms 700 Minute Ventilation 30 L/min 0 90 PET CO2 mmHg 0 100 SaO2 % 65 0 6 TIME (min)

  25. * † 20 15 Prevalence of diurnal CSR (%) Nocturnal apnea-hypopnea index 10 5 Normal chemoreflex Increased HVR Increased HCVR Increased HVR+HCVR Giannoni A, Emdin M, Poletti R, Bramanti F, Prontera C, Piepoli M, Passino C. Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne-Stokes respiration and arrhythmias. Clin Sci (Lond). 2007 Oct 26; [Epub ahead of print]

  26. VE/VCO2 slope peakVO2 ** ml/min/kg * NB CS NB CS * p<0.05, ** p<0.01 Giannoni A, Emdin M, et al.. Clin Sci (Lond). 2007 Oct 26; [Epub ahead of print]

  27. NT-proBNP NorEPI BNP pg/ml ** *** *** NB CS NB CS NB CS ** p<0.01, *** p<0.001 Giannoni A, Emdin M, et al.. Clin Sci (Lond). 2007 Oct 26; [Epub ahead of print]

  28. Multivariate Analysis • CO2-sensitivity and BNP level are independent predictors of CSR (also considering O2-sensitivity, peak VO2, VE-VCO2 slope, norepinephrine, NT-proBNP from univariate analysis)

  29. CO2-sensitivity andBNP aspredictors of CSR HCVR slope Sensitivity AUC 0.93 P<0.001 BNP AUC 0.89 P<0.001 Specificity

  30. chemoceptors  Norepi  BNP, ANP CSR hypoxia LV dysfunction altered haemodynamics

  31.  baroreflex  ergo-chemoreflex BNP - ANP system activation >>> Sympathetic - RAA activation Na - H20 retention – vasoconstriction arrhythmogenesis – tissue ischaemia arrhythmias dyspnoea fatigue sudden death oedema NEURO-HORMONAL IMBALANCE IN HEART FAILURE LV DYSFUNCTION

  32. 60 sec. CSR in CHF: therapeutical target? • Why? • To improve respiratory pattern • To improve sleep quality/QOL • To improve cardiac performance • To improve prognosis (?) • When? • Which patient? • Which marker (daytime abnormalities, PSG-AHI, BNP, …)? • How?

  33. 60 sec. Diagramma del trattamento del respiro di Cheyne Stokes nello scompenso cardiaco Scompenso cardiaco con respiro di Cheyne-Stokes Ottimizzare la terapia per CHF. (farmaci, CRT) Assenza di Cheyne-Stokes Cheyne-Stokes persiste Considerare un trattamento specifico O2 terapia CPAP o altri device (Trapianto Cardiaco) Metilxantine

  34. N Engl J Med 2005;353:2025-33.

  35. Grazie per l’attenzione! emdin@ifc.cnr.it passino@ifc.cnr.it

  36. NYHA CLASS LVEF * * % NB CS NB CS * p<0.05 Giannoni A, Emdin M, et al.. Clin Sci (Lond). 2007 Oct 26; [Epub ahead of print]

  37. Effect of Theophylline on Sleep-Disordered Breathing in Heart Failure S. Javaheri et al. NEJM August 22,1996 n8 335:562-567 Protocollo dello studio: 15 pz con scompenso cardiaco e disturbi della respirazione notturni (AHI > 10/ora). Somministrazione orale di Teofillina o placebo 2 volte die per 5 gg con una settimana di washout fra i due periodi. Risultati: Significativa riduzione degli episodi di apnea/ipopnea rispetto al placebo: Placebo 47  37 Teofillina 47  18 Possibili meccanismi della Teofillina: Competizione a livello centrale con il sito recettoriale dell’Adenosina (depressore respiratorio) Incremento del deficit ventilatorio polmonare restrittivo associato allo scompenso cardiaco Effetto inotropo

  38. Analisi tramite algoritmo GSTFT Rappresentazione tempo-frequenza del segnale EEG (C4 –A1) in un soggetto con scompenso cardiaco senza respiro di Cheyne-Stokes

  39. Bi-level PAP may fit the abnormal breathing pattern of CSR-CSA better than CPAP. Therefore, bi-level PAP improves an abnormal breathing pattern more immediately and effectively than CPAP. In a recent study, it has been reported that 57% of patients showed no response to CPAP

  40. Benefit of Atrial Pacing in Sleep Apnea SyndromeNEJM February 7, 2002 n 6, 346: 404-412 Stephane Garrigue, M.D., Philippe Bordier, M.D., Pierre Jaïs, M.D., Dipen C. Shah, M.D., Meleze Hocini, M.D., Chantal Raherison, M.D., Manuel Tunon De Lara, M.D., Michel Haïssaguerre, M.D., and Jacques Clementy, M.D. 15 pz con OSA e PM bicamerale AHI in ritmo spontaneo: 28 AHI in ritmo elettroindotto 11 (P<0.001) PRO CONTRO

  41. CHF-N CHF-OSA CHF-CSA Increased long-term mortality in heart failure due to sleep apnoea is not yet proven T. Roebuck1, P. Solin1, D.M. Kaye2,4, P. Bergin2, M. Bailey3 and M.T. Naughton1 Eur Respir J. 2004 May;23:735-40 78 pazienti LVEF 19.9 ± 7.2% PCP 16.5 ± 8.3 mmHg

  42. Effetti clinici del respiro di CS • Cicli di desaturazione arteriosa • Ipossia  disfunzione d’organo/danno endoteliale, vasocostrizione polmonare • Iperattivazione simpatica • Diretta • Indiretta in risposta all’ipossia • Effetti emodinamici (prevalentemente indiretti) •  FC, vasocostrizione

  43. Overall CO2 sensitivity vs adrenergic activation and ventilatory efficiency 70 10000 R=0.322 P<0.05 R=0.549 P<0.001 60 1000 50 NEPI (pg/ml) VE-VCO2 SLOPE 40 100 30 20 10 0.5 0.0 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 CO2 SENSITIVITY CO2 SENSITIVITY

  44. Overall CO2 sensitivity vs B-type Natriuretic Peptides 70 10000 R=0.411 P<0.01 R=0.400 P<0.01 R=0.549 P<0.001 R=0.322 P<0.05 60 1000 50 NT-proBNP (pg/ml) BNP (pg/ml) 40 100 30 20 10 0.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 0.5 1.0 1.5 2.0 CO2 SENSITIVITY CO2 SENSITIVITY

  45. CONCLUSIONS CSR is associated with: • Enhanced chemoceptive sensitivity to O2 and CO2 • Symptom severity and systolic dysfunction • Functional capacity and ventilatory efficiency • Adrenergic activation • BNP/NT-proBNP levels CSR is predicted by: • Enhanced chemoceptive sensitivity to CO2 • BNP plasma level

More Related